{
  "input": {
    "mode": "score",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        }
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        }
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        }
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        }
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        }
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        }
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        }
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        }
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        }
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        }
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        }
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        }
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_tnf_alpha",
          "type": "Target",
          "label": "TNF-α",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammation",
          "type": "Pathway",
          "label": "Inflammation Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised Pustular Psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "Off-target Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "Risk Pathway Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "Adverse Phenotype Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_adalimumab",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，常用于化脓性脓疱型银屑病"
        },
        {
          "source": "drug_etanercept",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，已知对该病有效"
        },
        {
          "source": "drug_infliximab",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，能改善皮肤症状"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "可通过干扰炎症通路影响该病"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "作用于IL-12与IL-23通路，降低炎症"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过抑制IL-17通路减轻症状"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过作用于IL-23途径改善症状"
        },
        {
          "source": "drug_guselkumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过调节炎症反应，改善相关症状"
        },
        {
          "source": "drug_apremilast",
          "target": "pathway_inflammation",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "通过PDE4抑制作用降低炎症"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammation",
          "relation": "inhibits",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "抑制免疫反应，可能改善症状"
        },
        {
          "source": "drug_cyclosporine",
          "target": "pathway_inflammation",
          "relation": "inhibits",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制，可能对病情有促进作用"
        },
        {
          "source": "drug_acitretin",
          "target": "pathway_inflammation",
          "relation": "modulates",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "可通过调节角质形成细胞作用改善病情"
        },
        {
          "source": "target_tnf_alpha",
          "target": "pathway_inflammation",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-α在炎症通路中的关键作用"
        },
        {
          "source": "pathway_inflammation",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症反应与该疾病密切相关"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能非特异性靶点影响"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路确立"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若此风险成立，药效可能受限"
        }
      ],
      "round_index": 2
    },
    "history": {
      "round": 2,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.68,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Adalimumab efficacy",
                "pro": [
                  "H1"
                ],
                "con": [
                  "n_adv_adalimumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab通过TNF-α靶向作用，在炎症通路中相关性强"
            ],
            "safety_risk": [
              "潜在的非特异性靶点风险可能导致疗效限制"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H2",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.75,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Etanercept efficacy",
                "pro": [
                  "H2"
                ],
                "con": [
                  "n_adv_etanercept"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept通过TNF-α靶向作用，已知对该病有效"
            ],
            "safety_risk": [
              "潜在的不良反应风险影响疗效评估"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H3",
          "score": 0.66,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Infliximab efficacy",
                "pro": [
                  "H3"
                ],
                "con": [
                  "n_adv_infliximab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab通过TNF-α靶向作用，能改善皮肤症状"
            ],
            "safety_risk": [
              "与不良表型的相关性需要进一步关注"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H4",
          "score": 0.64,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.75,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Secukinumab efficacy",
                "pro": [
                  "H4"
                ],
                "con": [
                  "n_adv_secukinumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab可通过干扰炎症通路影响该病"
            ],
            "safety_risk": [
              "不良反应风险和疗效的平衡需要继续观察"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H5",
          "score": 0.63,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Ustekinumab efficacy",
                "pro": [
                  "H5"
                ],
                "con": [
                  "n_adv_ustekinumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab通过作用于IL-12与IL-23通路降低炎症"
            ],
            "safety_risk": [
              "需关注潜在的安全性问题"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H6",
          "score": 0.61,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Brodalumab efficacy",
                "pro": [
                  "H6"
                ],
                "con": [
                  "n_adv_brodalumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Brodalumab通过抑制IL-17通路减轻症状"
            ],
            "safety_risk": [
              "潜在的不良表型可能影响治疗效果"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H7",
          "score": 0.6,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Tildrakizumab efficacy",
                "pro": [
                  "H7"
                ],
                "con": [
                  "n_adv_tildrakizumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Tildrakizumab通过作用于IL-23途径改善症状"
            ],
            "safety_risk": [
              "长期效应与安全性之间的潜在风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H8",
          "score": 0.62,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.65,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 2.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Guselkumab efficacy",
                "pro": [
                  "H8"
                ],
                "con": [
                  "n_adv_guselkumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Guselkumab通过调节炎症反应改善相关症状"
            ],
            "safety_risk": [
              "需要关注潜在的不良反应问题"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H9",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.55,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 1.5,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Apremilast efficacy",
                "pro": [
                  "H9"
                ],
                "con": [
                  "n_adv_apremilast"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Apremilast通过PDE4抑制作用降低炎症"
            ],
            "safety_risk": [
              "针对特定人群的疗效需进一步关注"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "无显著机制连通性，与其他疗法比较可能不足"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.55,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 1.2,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Methotrexate efficacy",
                "pro": [
                  "H10"
                ],
                "con": [
                  "n_adv_methotrexate"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate抑制免疫反应，可能改善症状"
            ],
            "safety_risk": [
              "不良反应可能影响疗效"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "缺乏直接联系至该疾病治愈的强证据"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 1.2,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Cyclosporine efficacy",
                "pro": [
                  "H11"
                ],
                "con": [
                  "n_adv_cyclosporine"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Cyclosporine通过免疫抑制作用可能对病情有促进作用"
            ],
            "safety_risk": [
              "需关注长期安全性问题"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "缺乏直接有效性证据"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.54,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.55,
            "indication_plausibility": 0.65,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.07
          },
          "graph_signals": {
            "support_weight": 1.2,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Acitretin efficacy",
                "pro": [
                  "H12"
                ],
                "con": [
                  "n_adv_acitretin"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin可通过调节角质形成细胞作用改善病情"
            ],
            "safety_risk": [
              "需要进一步观察其长期安全性"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "缺乏明确机制与病理的联系"
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "scoring_summary": [
      {
        "hypothesis_id": "H1",
        "score": 0.68,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.8,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Adalimumab efficacy",
              "pro": [
                "H1"
              ],
              "con": [
                "n_adv_adalimumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab通过TNF-α靶向作用，在炎症通路中相关性强"
          ],
          "safety_risk": [
            "潜在的非特异性靶点风险可能导致疗效限制"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H2",
        "score": 0.65,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.75,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Etanercept efficacy",
              "pro": [
                "H2"
              ],
              "con": [
                "n_adv_etanercept"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept通过TNF-α靶向作用，已知对该病有效"
          ],
          "safety_risk": [
            "潜在的不良反应风险影响疗效评估"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H3",
        "score": 0.66,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.8,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Infliximab efficacy",
              "pro": [
                "H3"
              ],
              "con": [
                "n_adv_infliximab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab通过TNF-α靶向作用，能改善皮肤症状"
          ],
          "safety_risk": [
            "与不良表型的相关性需要进一步关注"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H4",
        "score": 0.64,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.75,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Secukinumab efficacy",
              "pro": [
                "H4"
              ],
              "con": [
                "n_adv_secukinumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab可通过干扰炎症通路影响该病"
          ],
          "safety_risk": [
            "不良反应风险和疗效的平衡需要继续观察"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H5",
        "score": 0.63,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.7,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Ustekinumab efficacy",
              "pro": [
                "H5"
              ],
              "con": [
                "n_adv_ustekinumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab通过作用于IL-12与IL-23通路降低炎症"
          ],
          "safety_risk": [
            "需关注潜在的安全性问题"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H6",
        "score": 0.61,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.7,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Brodalumab efficacy",
              "pro": [
                "H6"
              ],
              "con": [
                "n_adv_brodalumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Brodalumab通过抑制IL-17通路减轻症状"
          ],
          "safety_risk": [
            "潜在的不良表型可能影响治疗效果"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H7",
        "score": 0.6,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Tildrakizumab efficacy",
              "pro": [
                "H7"
              ],
              "con": [
                "n_adv_tildrakizumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Tildrakizumab通过作用于IL-23途径改善症状"
          ],
          "safety_risk": [
            "长期效应与安全性之间的潜在风险"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H8",
        "score": 0.62,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Guselkumab efficacy",
              "pro": [
                "H8"
              ],
              "con": [
                "n_adv_guselkumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Guselkumab通过调节炎症反应改善相关症状"
          ],
          "safety_risk": [
            "需要关注潜在的不良反应问题"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H9",
        "score": 0.58,
        "components": {
          "mechanism_fit": 0.55,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 1.5,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Apremilast efficacy",
              "pro": [
                "H9"
              ],
              "con": [
                "n_adv_apremilast"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Apremilast通过PDE4抑制作用降低炎症"
          ],
          "safety_risk": [
            "针对特定人群的疗效需进一步关注"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "无显著机制连通性，与其他疗法比较可能不足"
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.55,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Methotrexate efficacy",
              "pro": [
                "H10"
              ],
              "con": [
                "n_adv_methotrexate"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate抑制免疫反应，可能改善症状"
          ],
          "safety_risk": [
            "不良反应可能影响疗效"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "缺乏直接联系至该疾病治愈的强证据"
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.58,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Cyclosporine efficacy",
              "pro": [
                "H11"
              ],
              "con": [
                "n_adv_cyclosporine"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Cyclosporine通过免疫抑制作用可能对病情有促进作用"
          ],
          "safety_risk": [
            "需关注长期安全性问题"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "缺乏直接有效性证据"
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.55,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.07
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Acitretin efficacy",
              "pro": [
                "H12"
              ],
              "con": [
                "n_adv_acitretin"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin可通过调节角质形成细胞作用改善病情"
          ],
          "safety_risk": [
            "需要进一步观察其长期安全性"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "缺乏明确机制与病理的联系"
        ]
      }
    ],
    "ranking": [
      "H1",
      "H3",
      "H2",
      "H4",
      "H5",
      "H6",
      "H8",
      "H7",
      "H9",
      "H11",
      "H10",
      "H12"
    ],
    "delta_since_last_round": 0.05,
    "stop_decision": {
      "should_stop": false,
      "reasons": [
        "Δscore≥0.03"
      ]
    }
  }
}